'The Top Line': How to support patients during a drug shortage, plus this week's headlines
04 Aug 2023
Gene TherapyClinical Study
Preview
Source: FiercePharma
None
In this episode of "The Top Line," Zoey Becker talks with Dr. Andrew Norden, Chief Medical Officer at OncoHealth, about the ongoing chemotherapy shortage sweeping the nation and what oncologists and health insurance companies can do to best support patients amidst these supply chain issues.
We also cover the a single-injection treatment for sickle cell disease, battery-powered gene therapy, and the rest of the week's headlines.
To learn more about the topics in this episode:
National cancer group reports widespread chemo shortages, calls on government and industry to help resolve them
FDA to allow temporary overseas production to shore up supplies of chemo drug
FDA can't solve drug shortages on its own, agency's oncology chief says
FDA links 4 deaths to recalled Abiomed Impella pumps after TAVR collisions
Quest launches blood test for Alzheimer's disease aimed at general consumers
One injection to cure sickle cell? Researchers give it a shot with new mRNA gene therapy
With 3 AA batteries and 2 acupuncture needles, a device controls gene expression in live mice
"The Top Line" and "Podnosis" are produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.